NFE2L2 and early-onset autosomal dominant Alzheimer disease: However, since DYRK1A overexpression in Down’s Syndrome (DS) is strongly implicated in DS-associated oxidative stress, Alzheimer’s disease [91], and motor dysfunction [90], DYRK1A inhibitors may be beneficial in this condition, e.g., by upregulating the nuclear factor erythroid 2-like 2 (NRF2) [92].